Sheet	1	1						=		
INFORMATION RISCECTORE CITATION WAY 1 5 2002			ATTY. DOCKET NO.		SERIA	L NO.	요	J		
				1331-353		09/9	64,514	MAY :	Ш	
			4	APPLICANT				NTE	Ω	
• .	. 4			von BORSTEL et al			0	-111	<u>m</u>	
	(Use several singets if necessary)					GROU	·F	2002 (600/	\leq	
· ADEAD			September 28, 2001 U.S. PATENT DOCUMENTS				2002	Щ		
*EXAMINE	R			J.S. PATENT						G DATE
INITIAL	$\neg \Gamma$	DOCUMENT NUMBER	DATE	Γ	NAME		CLASS	SUBCLASS	IF APPR	OPRIATE
	\perp									
	\bot									
	╫			 				<u> </u>		
	+				-					
	+			<u> </u>				<u> </u>		
·	╁							-		
	1									
	+								_	
	+									
			10.0							
	4							·		
	+				·					
		<u> </u>	FO	REIGN PATE	NT DOCUMENT	 'S			-	
		DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS YES	LATION NO
	Т	DOCUMENT	DAIL		COONTAI	• •	CLASS	SUBCLASS	169	NO
	上									
	-							-		
	+									
			·							
	П	OTHER DOCU	MENTS (I	Including Aut	hor, Title, Date,	Pertinent	pages, o	etc.)		
		Eliseev et al, Khim-Fam	Zh, Vol.	19, pp. 694-6	96 (1985)					
	H			_		_				
	H									
Examiner	-	House &			Date Conside	red	8-3	rock		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

Sheet	1	of	2				•		14 p. 10	
INFORMATION DISCLOSUR		SURE	ATTY.	DOCKET NO.	SERIA	L NO.		<u>v</u> .		
	CITATION				¥7			- 5 5		
		1331-353 APPLICANT		Unassigned			- %	-		
				APPLI	CANI	-			54	
				von	BORSTEL et al				ט	==
	(Use e	several sheets if necessar	ry)	FILING	DATE	GROU	P		-	
		•		Sent	ember 28, 2001					
					U.S. PATENT DOCUMENTS					
*EXAMINE	R				U.S. PATENT BOODINERTO				FILING	DATE
INITIAL		DOCUMENT NUM		DATE	NAME		CLASS	SUBCLASS	IF APPR	OPRIATE
	<u> </u>	3,585,188	_	6/1971	Ryuji			_		
	\perp	3,991,045		11/1976	Ichida et al					
		3,847,898		1771974	Kelly				<u> </u>	
		4,022,963		5/1977	Deutsch / Y'	Δ	/1			
		3,975,367		8/1985~	Gish et al	1		/		<u> </u>
		4,868,162		9/1989	Kawaguchiletal					
	\perp	3,894,000		7/1975	Wechter et al				ļ	
		3,868,451		2/1975	Stein et al					
		6,258,795		7/2001	von Borstel et al				l	
		·		FC	DREIGN PATENT DOCUMENTS					
		200111512		2.75	00111701		01.400	611001.400		LATION
<u> </u>		DOCUMENT		DATE	COUNTRY		CLASS	SUBCLASS	YES	NO
<u>X40</u>	\perp	1,473,148		5/1977	U.K.					
	44	51019770		-2/1076-	Japan					
	\bot	0023085		-2/1977 -	Japan					
		<_0049315		-3/1983 -	Japan		•			
<i>\$40</i>		0222192		5/1987	European		#E-		-	
	\perp	-0178217		4/1986	European					
	\bot	° 57 91 995		-6/1982	Japan —					
		55-24150		3/1983	Japan					
	44	- ≥38-49315		2/1980	Japan					
270	$\perp \perp$	1297398		11/1972	Great Britain					
	Ш	-2 147 094		-4/1973 -	Germany					
	\perp	= 0.058.265		1/1982	EPO			,		
	1-	<u></u>		2/1984	Japan					
	$\perp \perp$				·					
					including Author, Title, Date, Pe	ertinent	pages, e	etc.)		
XD_					n., 28:1541-1545, 1979.					
HO HO HO HO HO HO		Martin et al, J. Pi	harm.	Sci. , Vol.	76, No. 2, 180-184 (1987).					
<i>PP</i>					ed. Julius Grant, ed. pp. 44, 45, 3	32-333,	<u> 1976.</u>			
140					ls, 74:112368K (1971).					
170					stracts, 92:105249r (1980).					
W.					acts, 87:194780u (1977).					
XI					:145-151 (1983). 247-256 (1984).					
100		Aussedat et al, ".								
AR HO		Buckley et al, *C								
					ksikol." 2:1 70-173 (1981).					
the					l.,° 10:545-565 (1978).		.			
/ -		Vicerson et al. "I								
AD					nal," 5:155-162 (1984).					
					0:694 -688 (1985).					
X/D		Villiams et al, "A	ust. N	.Z. J. Med.	,* 6:Supp. 2, 60-71 (1976).					
960					655-659 (1982).					

Hound Colo

8-4-04

•	•			
.Sheet .	1 f 2	•		
,0,10,11	,			∞ 2 = 5
INFO	RMATION DISCLOSURE	ATTY, DOCKET NO.	SERIAL NO.	26 E8
	CITATION	1331-353	Unassigned	\$6
		APPLICANT		5
		von BORSTEL et al		
ņ	Jse several sheets if necessary)	FILING DATE	GROUP	
		00.0001		
		September 28, 2001		
	OTHER DOCUMENTS	(including Author, Title, Date	, Pertinent pages, etc.) contin	ued
CK	Kypson et al, "Biochem.	Pharmacol.," 26:1585-1591 (197	77).	
	Pastoris et al, "Pharm. E	d. Sci.,* 40:442-453 (1985).		
		Exp. Ther.,* 199-565-574 (1976))	
	Gasser et al, "Science" 2	213:777-778 (1981).		
	Klubes et al, "Cancer Ch	emother. Pharmacol." 17:236-24	10 (1986).	
		Phys. Acta,* 174-491-502 (1969)		
		Biol. Med.",88:1480-1483 (1980		
CK	Chemukh et al, "Buil. Ex	p. Biol. Med.," 70:1112-1114 (19	970).	
		chim. Biophys. Acta, 57:583-58	7_(1962).	
Zx	Elrick et al, "Metabolism"	11:46-55 (1962).		
	Yamada et al, "J. Biol. C	hem.* 243:1649-1655 (1968).		
	Shah et al, "J. Anim. Mo	rphol. Physiol." 25:193-200 (1978	8)	
	Shah et al, "J. Anim. Mo	rphol. Physiol." 21:132-139 (1974	4)	
-CX	Songu et al, "Metabolism	n* 30:119-122 (1981).	<u></u>	
	Germanyuk et al, Farma	kol. Toksikol: 50-52 (1979).		
		emical Research® 9:73-79 (1984		
<u>CL</u>	Dwivedi et al, "Toxicol. A	ppl. Pharmacol." 31:452 (1978).		
<u> </u>	Geiger et al, "J. Neuroch			·
-	Sepe, Minerva Medica,			
	Jann et al, "Minerva-Med	lica; " 60:2092 (1969)		
CK	Beranek et al, "Collection	Czechslovak Chem. Commun.,	<u>* 42:366-369 (1977).</u>	
Cit	Sasaki et al, *Chem. Pha	arm. Bull," 15:894-896 (1967).	<u> </u>	
distraction.		ad-Sci-USSR-Div-Chem-Sci-	30:1306-1310 (1981):	
GK.	Watanabe et al, "Angew.		<u> </u>	<u> </u>
		n Letters," 29:2459-2465 (1965).		
	Lortet et al, The Chemica	al Abstracts, 105:112608y (1986))	
		ardiol. 81:303-310 (1988).		
	Lim et al. "Antimicrobiol	Agents and Chemotherapy, 31:9	98-1001 (1987).	
	Rosowsky et al, "Cancer	Treatment Reports 85(1-2); 93-9	99 (1981).	
		mother. Pharmacol. 24:9-14 (198	89)	
1	Cacida et al Binchem P	harm 15:627-644 (1966)	<u>.</u>	

*Examiner

Examiner: Initial if reference considered, whether or not obtain is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Form PTO-FB-A820 (Also PTO-1449)

5/18/00

1 Shugat SERIAL NO. INFORMATION DISCHOTS VERE ATTY, DOCKET NO. CITATION 09/964,514 1331-353 Ш APPLICANT 7. HOV 1 5 2001 von BORSTEL et al GROUP (Use several sh FILING DATE မ & TRADEM September 28, 2001 U.S. PATENT DOCUMENTS **EXAMINER** SUBOS CLASS NAME INITIAL DOCUMENT NUMBER DATE #5 6/1971 Marumoto et al 3,585,188 Stein et al 2/1975 3,868,451 Gish; et al 3,975,367 8/1976 11/1976 Ishida et al 3,991,045 5/1977 Deutsh 4,022,963 Kawaguchi et al 9/1989 4,868,162 3,847,898 11/1974 Kelly et al 7/1975 Wechter et al 3,894,000 9/1989 Kawaguchi et al 4.868,162 7/2001 von Borstel et al 6.258.795 **FOREIGN PATENT DOCUMENTS** TRANSLATION **SUBCLASS** COUNTRY CLASS YES NO DOCUMENT DATE X 2147 094 Суупару Great Britain 1-297-398 Great Britain 4-473-148 51-19719) Japan X -52-23085 Japan X X ·58-49315 Japan 57-91995 Japa/ X X 55-24150 Japan 60) 1124787 L lapan *

Chemical Abstracts, The American Chemical Society, Vol. 27, No. 25, p. 152 (1977).

Chemical Abstracts, The American Chemical Society, Vol. 87, No. 25, p. 152 (1977).

Chemical Abstracts, The American Chemical Society, Vol. 87, No. 25, p. 152 (1977).

Chemical Abstracts, The American Chemical Society, Vol. 87, No. 25, p. 152 (1977).

Chemical Abstracts, The American Chemical Society, Vol. 87, No. 25, p. 152 (1977).

Chemical Abstracts, The American Chemical Society, Vol. 87, No. 25, p. 152 (1977).

Aussedat, J., "Effect of uridine surply on glycogen resynthesis," Cardiovascular Research, Vol. 17, pp. 145-151 (1983).

Aussedat et al, "Uridine Incorporation in Norman..., Molecular Physiology, Vol. 6, pp. 247-256 (1984).

Buckley et al, "Effects of Nucleosides on Acule Left...," Circulation/Research, Vol. Vil. pp. 847-857 (1959).

Kuznetsova et al, "Effects of Oridine on the Performance..." Journal of Molecular and Cellular Cardiology, Vol. 10, pp. 545-565 (1978).

Rossi et al, "Pyrimidine nucleotide metabolism in cardiac hypertrephy," European Heart Journal, Vol. 5, pp.

ΕP

ŘΡ

Hand Do

155-162 (1984).

0 056 266 B) L

A/1986

5/1987

Meerson et al, Kardiologiva, Vol. 25 (1985).

0 178 2

0 222 192/A2

8-4-04

X

X

/	·								
					=				
· Sheet	41 f 1				TECH	-			
111505	MATION DICK ACROSE	ATTY. DOCKET NO.		SERIAL NO.					
INFOR	RATION DISCLARATE CONTAINS				CEN:	EC			
	CITATION	<u>1331-353</u>		09/964,514		-			
,		APPLICANT				m			
	[KDV 1 5 2001 gg	von BORSTEL et	al		6 2				
(U	to several shape in necessary) ARADE MATERIAL	FILING DATE		GROUP	2001 600/2	E .			
	PAREMAR	Contombor 28, 20			156	<u> </u>			
	OZUED DOGUM	September 28, 20		tinent negee :etc '	ຸຮ	O,			
7 10	Williams et al, "Studies Us	ENTS (including Aut	Supplement 2 Vol	6 Aust N.Z.I Mai	d pp. 60-71	(1976).			
	Kypson et al, 'Effects of U	tridine ".loumal of M	elecular and Cellular	Cardiology, Vol. 1	D. pp. 545-56	55 (1978).			
<u>use</u>	-Meerson et al, Kardiologiv								
Cic	Rossi et al, "Pyrimidine nu	cleotide metabolism i	n European Hear	t Journal, Vol. 5, pr	. 155-162 (1	984).			
	Williams et al, "Studies U	sing Orotic Acid" Su	pplement 2, Vol. 6, A	Aust. N.Z.J. Med., p	p. 60-71 (19	76).			
	Swain et al, "Derangemer	tsin myocardial purine	, Proc. Natl. Acad	J. Sci. USA, Vol. 79	, pp. 655-65	9 (1982).			
	Kypson et al, "Metabolic E	ffects of Inosine and	., Biochemical Phar	macology, Vol. 26,	pp. 1585-15	91 (1977).			
	Pastoris et al. "Modification	n of the skeletal musc	le," Pharm. Ed. Sc	i., Vol. 40, p. 442-4	53 (1985).				
	Kypson et al, "Effects of u	ridine and inosine on	lucose,* The Jour	nal of Pharmacolog	y and Exper	imental			
	Therapeutics, Vol. 199, N	o. 3, pp. 565- <u>574 (</u> 197	6).						
	Gasser et al, "Novel Singl	e-Pass Exchange,	Science, Vol. 213, p	p. 777-778 (1981).					
	Kubes et al, "Comparison	of the bioavailability	, Cancer Chemothe	r Pharmacol, Vol.	7, pp. 236-2	40 (1986).			
	Bucher et al, 'Ribonucleio	acid synthesis in rela	tion, Biochim. Bio	phys. Acta, Vol. 174	4, pp. 491-50)2 (1969). `			
	Bushma et al, "Effect of C	ytidine and Uridine,	Bull. Exp. Biol. Med	I., Vol. 88, pp. 1480	<u>-1483 (1980</u>). 1070\			
$\overline{}$	Chernukh et al, Effect of	Chernukh et al, "Effect of liver RNA on the course," Bull. Exp. Biol. Med., Vol. 70, pp. 1112-1114 (1970).							
	Diamondstone et al, "Diffe	Diamondstone et al, "Differential Response of Inducible," Biochim. Biophys. Acta., pp. 583-587 (1962).							
	Elrick et al, "Influence of Certain Nucleosides," Metabolism, Vol. Xi, No. 1, pp. 46-55 (1962) Yamada et al, "Pyrimidine Nucleoside Phosphorylases of Rat Liver," The Journal of Biological Chemistry, Vol.								
l l	Yamada et al, "Pyrimidine Nucleoside Phosphorylases of Hai Liver," The Journal of Biological Chemistry, vol. 243, No. 7, Issue of April 10, pp. 1649-1655 (1968).								
	Shah et al, "Wound healir	on and renair ".l Ani	m. Morphol. Physiol	. Vol. 25. No. 1 and	12. pp. 193-	200 (1978).			
	Shah et al, "Wound healir	ng and repair* J. Ani	m. Morphol. Physiol	., Vol. 21, No. 2, pp	. 132-139 (1	974).			
73K	Songu et al, 'The Relation	ship Between Uracil I	lucleotide, Metab	olism, Vol. 30, No.	2, pp. 119-12	22 (1981).			
	Germanyuk et al. Garmal	ol. Tokksikol. Vol. 45.	No1, pp50-52-(-19	79)					
CAC	Trovarelli et al, "The influe	ence of cytidine on the	endogenous pool	Neurochemical R	esearch, Vol	l. 9, No. 1,			
$\overline{}$	pp. 73-78 (1984).								
_CX	Dwivedi et al, "Anticonvul	sant," Toxicology ar	d Applied Pharmace	ology, Vol. 31, pp. 4	52-458 (197	<u>5). </u>			
E	Geiger et al, *Cytidine and	Uridine Requirement	," Journal of Neuroc	hemistry, Vol. 1, p	o. 93-100 (19)56).			
	Sepe, O., "Efficacia dell'a	ssociazione citiolina-ur	idina, Minerva Me	oca, pp. 5934-594	0.				
712	pann et al, "Azione della d Beranek et al, "Selective	Condetion Collection	nnerva wedica; pp:	m Commun (Vol.	12) nn 367-1	369 (1977)			
C.K	Sasaki et al, "Selective A	racylation, Collection	"Chem Pharm Pi	il Vol 15 No 6 s	D SOV-COL	1967).			
Cok	Samoilova et al, "Polyerm	Je N. Hadrovenccinim	ide • Bull Acad S	cl USSA Div Cher	n Sci Vol 3	30. pp.			
Œ	1306-1310 (1981).	iic iv-riyuloxysucciiliii	100, Dull. 7000. O	UI. 00011 DIV. 01101	001. 701. 1	, pp.			
	Watanabe et al, "Eine ein	fache Methode zur se	ektiven* Agnew. C	hem., Vol. 78, Jahr	g. 1966-/-Nr.	11.			
GK	Reese et al. "2'-O-acyl Ri	ponucleoside Derivativ	res," Tetrahedron Le	tters, No. 29, pp. 2	459-2465 (19	965).			
	Chemical Abstracts, The	American Chemical Sc	ciety, Vol. 105, No.	13, p. 456 (1986).					
	Lortet et al. "Pyrimidine n	ucleotide synthesis"	Basic Res. in Card	iol. Vol. 81, pp. 302	-310 (1986).				
	Schwartz et al, "Evaluatio	n of (+)-Cyclaradine-5	-Esters, Antimicro	obial Agents and C	nemotherapy	, Vol. 31,			
	No. 7, pp. 998-1001 (1987). Rosowsky et al, "Thymidine 5'-O-pivaloate" Cancer Treatment Reports, Vol. 65, No. 1-2, pp. 93-99 (1981).								
	Rosowsky et al, "Thymidi	ne 5'-O-pivaloate" C	ancer Treatment Re	ports, Vol. 65, No. 1	-2, pp. 93-9	*1000)			
1	Martin et al, "Use of oral u	ingine as a substitute.	, Cancer Chemoin	er Pharmacol, Vol.	24, pp. 3-14 644 (1066)	1303].			
<u>U</u> C	Casida et al, "3",5"-Dieste	S OI 5-IIUOIO, BIOCH	emicai Friamnacolog	y, voi. 13, pp. 621.	<u> </u>				
*Examiner	12 50 1		Date Considered	-1151	O0 .				
	Granil		20.2 20.00.00.00						

Examiner: Intital if reterence considered, whether or not citation is in contournance with MPEP 609; Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)